News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

e-Therapeutics plc Temporary Halts Recruitment Into ETS2101 Cancer Trials

1/24/2014 6:20:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

e-Therapeutics announces temporary halt of recruitment into ETS2101 cancer trials because of drug supply issue

Oxford and Newcastle, UK, 24 January 2014 – e-Therapeutics plc (AIM:ETX) today announces that recruitment of patients into both of the ongoing phase I trials of ETS2101 has been halted temporarily because of a practical issue with stored drug for the trials. Patients already receiving treatment with ETS2101 will continue to be dosed in accordance with trial protocols. Relevant regulators are being notified and the Company is taking steps to enable recruitment to resume as soon as possible.

Two phase I studies of ETS2101 are ongoing: an investigator-led study in brain cancer at the UC San Diego Moores Cancer Center in La Jolla, California and a study at three UK centres that is enrolling patients with a variety of solid tumours. A report of data from the UK study had been expected in Q1 2014; this may be delayed by the temporary halt in recruitment.

About e-Therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is focused in cancer and disorders of the nervous system. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit

About ETS2101

ETS2101 (dexanabinol) is a synthetic cannabinoid previously studied in trauma patients. Application of network pharmacology by e-Therapeutics suggested that the drug has potential in cancer. Preclinical studies then provided evidence of activity in a wide variety of cancer cell lines. Two phase I studies of ETS2101 are ongoing, one in patients with primary or secondary brain cancers and one in patients with various advanced solid tumours. Issued for and on behalf of e-Therapeutics by College Hill.

For more information please contact:

e-Therapeutics plc
Malcolm Young / Daniel Elger
Tel: +44 (0) 7909 915 068
Panmure Gordon (UK) Limited
Fred Walsh / Grishma Patel / Duncan Monteith
Tel: +44 (0) 20 7886 2500
College Hill
Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill
Tel: +44 (0) 20 7457 2020
CommStrat Group (US)
Ted Agne
Tel: (+1) 781 631 3117

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus